EpiNet-First Trial 2: Comparison of efficacy of levetiracetam and sodium valproate in people with previously untreated epilepsy who have generalised seizures.
EpiNet First Trial 2: A pragmatic randomised controlled trial comparing the effectiveness of levetiracetam versus sodium valproate in people with previously untreated epilepsy who have generalised seizures.
EpiNEt Study Group
506 participants
May 11, 2015
Interventional
Conditions
Summary
Levetiracetam is being compared with sodium valproate in patients with new-onset epilepsy who have generalised seizures. Four other closely related trials are being conducted, with the entry criteria for each trial determined by the seizure type that the patient experiences. Sustained seizure freedom (at least 12 months seizure free) is the primary endpoint
Eligibility
Inclusion Criteria5
- -Aged 5 years or older on date of consent
- -The investigator is confident that the patient has epilepsy
- -Two or more spontaneous generalized seizures that require antiepileptic drug treatment (provided all seizures have not been absence seizures);
- -Antiepileptic drug monotherapy considered the most appropriate option
- -Willing to provide consent. For patients younger than the age of consent (usually 16 years), patient's parent/legal representative willing to give consent,
Exclusion Criteria6
- -Provoked seizures (e.g. alcohol, recreational drugs)
- -Acute symptomatic seizures (e.g. acute brain haemorrhage or acute brain injury)
- - absence seizures as only seizure type
- - Psychogenic non-epileptogenic seizures
- -Has ever been treated with an antiepileptic for more than one week
- -Known progressive neurological disease (e.g. brain tumour)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
EpiNet-First Trial 2: patients with generalised seizures for whom sodium valproate is suitable will be randomised (1:1) to receive levetiracetam or sodium valpoate. Levetiracetam. Oral medication. Duration of treatment administration = 2 years. Dose to be determined by investigator according to usual clinical practice. The range of doses will vary from 250 mg to 4000 mg (oral tablets) daily in two divided doses and will be determined as considered clinically appropriate by the investigator. Adherence will be assessed by the investigators checking regularly with patients whether they are taking the drug as prescribed. Serum drug levels are not required as part of the study, but will be monitored as determined by the investigator and considered appropriate for good clinical care.
Locations(8)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12615000556549